ArticleActa epileptologica2026
Clinical and neurophysiology study of 17 children with epileptic negative myoclonus.
Article in Acta epileptologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpileptic negative myoclonus (ENM) is a clinically underrecognized seizure type, and systematic data on its clinical manifestations and optimal management strategies in pediatric populations remain scarce. This case series aimed to describe the clinical manifestations, neurophysiological patterns, and therapeutic outcomes in pediatric ENM.
methodsA retrospective descriptive analysis was conducted on 17 ENM patients diagnosed at Wuxi Children's Hospital between October 2017 and June 2024. Clinical data, electroencephalogram (EEG) findings, and treatment responses were systematically evaluated.
resultsThe cohort showed a marked female predominance (female-to-male ratio of 12:5). All cases exhibited upper-limb ENM, with contralateral central-parietal epileptiform discharges observed in ictal EEG. Two patients presented additional lower-limb ENM accompanied by midline discharges. Clinically, ENM manifested as the initial symptom in five cases (29.4%), including two with isolated ENM. Therapeutic outcomes varied: among four non-electrical status epilepticus during sleep (ESES) patients, antiseizure medications (ASMs) achieved symptom control, including one case of oxcarbazepine (OXC)-associated ENM that resolved after transition to valproate (VPA). Of 13 ESES-positive patients, three responded to ASMs alone, while nine received methylprednisolone pulse therapy (MPT), and one surgical candidate with focal cortical dysplasia (FCD) type IIa achieved post-resection remission. Among the nine children treated with MPT: four showed a good response; four relapsed upon steroid withdrawal; and one responded well to ketogenic diet (KD) therapy.
conclusionsENM can manifest as the initial or sole epilepsy symptom in children. The marked female predominance in this cohort suggests that sex-related factors may play an important role in the expression or underlying mechanisms of ENM. Additionally, a correlation was found between the EEG discharge patterns and the specific limb regions involved. Regarding treatment, OXC may exacerbate ENM, necessitating cautious use. Steroid therapy should be considered for ESES cases unresponsive to ASMs. Refractory ENM with ESES warrants evaluation for structural abnormalities, particularly cortical dysplasia. Early EEG and neuroimaging improve diagnostic accuracy, while combined therapies-ASMs, immunomodulation, KD, or surgery-optimize outcomes. These findings highlight ENM's diagnostic intricacy and the need for individualized management. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.